A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05)
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Iron isomaltoside 1000 (Primary) ; Ferric carboxymaltose
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms IDA-05
- Sponsors Pharmacosmos
- 30 Aug 2018 Status changed from recruiting to completed.
- 28 Dec 2017 Status changed from not yet recruiting to recruiting.
- 04 Aug 2017 New trial record